Utilising the impact of COVID-19 on trauma throughput to adapt elective care models for more efficient trauma care

Table 5 Patient demographics, length of stay, comorbidity indices and theatre parameters for 2020

	Phase 0 (n = 640)	Phase 1 (n = 425)	Phase 2 (n = 1210)	Phase 3 (n = 413)	Total (n = 2688)
	mean ± SD
Age at injury	59.46 ± 23.95	62.16 ± 23.61	57.70 ± 24.07	60.97 ± 23.47	59.33 ± 23.93
Length of spell (d)	7.05 ± 7.87	5.69 ± 5.90	5.71 ± 7.54	7.53 ± 8.86	6.30 ± 7.64
Charlson Comorbidity Index	0.77 ± 1.23	0.90 ± 1.45	0.68 ± 1.19	0.68 ± 1.25	0.73 ± 1.26
Elixhauser Comorbidity Index	1.27 ± 1.46	1.55 ± 1.63	1.21 ± 1.37	1.19 ± 1.39	1.28 ± 1.44
Hours to surgery	30.71 ± 49.37	30.84 ± 34.56	24.50 ± 37.98	24.59 ± 37.14	26.97 ± 40.41
Time in theatre	95.62 ± 50.10	144.25 ± 64.24	127.98 ± 54.37	123.20 ± 54.48	122.11 ± 57.35
Time in theatre/recovery	215.97 ± 124.31	175.22 ± 117.92	195.23 ± 106.09	203.28 ± 132.37	199.65 ± 117.42
Sex: Female	347 ± 54.2%	237 ± 55.8%	649 ± 53.6%	234 ± 56.7%	1467 ± 54.6%
Sex: Male	293 ± 45.8%	188 ± 44.2%	561 ± 46.4%	179 ± 43.3%	1221 ± 45.4%